Mészáros, Tamás and Csincsi, Ádám and Uzonyi, Barbara and Hebecker, Mario and Fülöp, Tamás and Erdei, Anna and Szebeni, János and Józsi, Mihály (2016) Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro. NANOMEDICINE: NANOTECHNOLOGY BIOLOGY AND MEDICINE, 12 (4). pp. 1023-1031. ISSN 1549-9634
|
Text
Nano_CARPA_Real.pdf Download (797kB) | Preview |
Abstract
Hypersensitivity reactions to particulate drugs can partly be caused by complement activation and represent a major complication during intravenous application of nanomedicines. Several liposomal and micellar drugs and carriers, as well as therapeutic antibodies, were shown to activate complement and induce complement activation-related pseudoallergy (CARPA) in model animals. To explore the possible use of the natural complement inhibitor factor H (FH) against CARPA, we examined the effect of FH on complement activation induced by CARPAgenic drugs. Exogenous FH inhibited complement activation induced by the antifungal liposomal Amphotericin-B (AmBisome), the widely used solvent of anticancer drugs Cremophor EL, and the anticancer monoclonal antibody rituximab in vitro. An engineered form of FH (mini-FH) was more potent inhibitor of Ambisome-, Cremophor EL- and rituximab-induced complement activation than FH. The FH-related protein CFHR1 had no inhibitory effect. Our data suggest that FH or its derivatives may be considered in the pharmacological prevention of CARPA.
Item Type: | Article |
---|---|
Subjects: | Q Science / természettudomány > QR Microbiology / mikrobiológia > QR180 Immunology / immunológia |
SWORD Depositor: | MTMT SWORD |
Depositing User: | MTMT SWORD |
Date Deposited: | 08 Feb 2017 11:49 |
Last Modified: | 01 Feb 2018 00:15 |
URI: | http://real.mtak.hu/id/eprint/47559 |
Actions (login required)
Edit Item |